Experience

Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd. The transaction, which is expected to close in the fourth quarter…

Davis Polk advised the underwriters in connection with an initial public offering of 17,968,750 shares of common stock of Akcea Therapeutics, Inc., including shares sold pursuant to the…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $75 million initial public offering of common stock of Mersana Therapeutics…

Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9 million initial public offering of common stock of Jounce Therapeutics,…

Davis Polk is advising Roche Holding Ltd. in connection with the sale of an active pharmaceutical ingredients manufacturing facility in Florence, South Carolina, to Patheon N.V. Under the…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the initial public offering by iRhythm Technologies, Inc. iRhythm sold 7,238,235 shares…

Davis Polk advised AC Immune SA in connection with its $75.9 million U.S. initial public offering. AC Immune sold 6,900,000 of its common shares in the offering, which included 900,000…

Davis Polk is advising Aetna Inc. in connection with the sale by Aetna and Humana Inc. of certain of their respective Medicare Advantage assets to Molina Healthcare, Inc. for a total…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $719 million initial public offering by Patheon N.V. (“Patheon”). The IPO comprised…

Davis Polk advised McKesson Corporation on its creation of a new health care information technology company, which will combine substantially all of Change Healthcare Holdings, Inc.’s…